Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | PLG | P00747 | 1/20 | 0.60 |
| ▸ | PLAT | P00750 | 1/20 | 0.60 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.47 |
| ▸ | GABRP | O00591 | 1/20 | 0.42 |
| ▸ | GABRD | O14764 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.42 |
| ▸ | GABRE | P78334 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14643284 | 1.00 | LMNA (0.60) | LMNAPLGPLATANPEPENPEP | |
| SCHEMBL879831 | 1.00 | LMNA (0.60) | LMNAPLGPLATANPEPENPEP | |
| Cyclopropane Carboxylic Acid SCHEMBL11636034 | 1.00 | LMNA (0.60) | LMNAPLGPLATANPEPENPEP | |
| Hydrochloric Acid SCHEMBL8903649 | 0.98 | PLG (0.58) | LMNAPLGPLATANPEPENPEP | |
| Hydrochloric Acid SCHEMBL11310028 | 0.98 | PLG (0.58) | LMNAPLGPLATANPEPENPEP | |
| SCHEMBL2820878 | 0.93 | PLG (0.54) | LMNAPLGPLATANPEPENPEP | |
| SCHEMBL2820876 | 0.93 | PLG (0.54) | LMNAPLGPLATANPEPENPEP | |
| SCHEMBL27324720 | 0.93 | LMNA (0.54) | LMNAPLGPLATANPEPENPEP | |
| SCHEMBL2820881 | 0.93 | PLG (0.54) | LMNAPLGPLATANPEPENPEP | |
| SCHEMBL3270204 | 0.93 | PLG (0.54) | LMNAPLGPLATANPEPENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004071448-A2 | SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | TRANSTECH PHARMA INC. (US) | 2004-08-26 | — | — | WO | claimed |
| EP-0285617-B1 | LIQUID CRYSTAL PHASE | MERCK PATENT GmbH (DE) | 1991-12-27 | — | — | EP | claimed |
| JP-6128196-A | — | — | None | — | — | JP | disclosed |
| EP-3990569-B1 | NEW POLYMERIZABLE LIQUID CRYSTAL | ROLIC TECH AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| CN-118702646-A | Novel polymerizable liquid crystal | 罗利克技术有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
| CN-114026078-B | Novel polymerizable liquid crystal | 罗利克技术有限公司 | 2024-06-07 | — | — | CN | disclosed |
| US-20230381177-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2023-11-30 | — | — | US | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-11702595-B2 | Polymerizable liquid crystal | Rolic Technologies AG (CH) | 2023-07-18 | — | — | US | disclosed |
| EP-0394906-A2 | Liquid crystalline composition | MERCK PATENT GmbH (DE) | 1990-10-31 | — | — | EP | disclosed |
| EP-0334911-A1 | SUBSTITUTED PHENYLTRIFLUORMETHYLETHERS | MERCK PATENT GmbH (DE) | 1989-10-04 | — | — | EP | disclosed |
| WO-1989002884-A1 | SUBSTITUTED PHENYLTRIFLUORMETHYLETHERS | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1989-04-06 | — | — | WO | disclosed |
| US-4786332-A | TOBACCO PRODUCTS | GIVAUDAN CORPORATION (US) | 1988-11-22 | — | — | US | disclosed |
| EP-0110362-B1 | FRAGRANCE AND FLAVOUR COMPOSITIONS | L. GIVAUDAN & CIE Société Anonyme (CH) | 1988-04-20 | — | — | EP | disclosed |
| US-4606925-A | Flavoring with alkyl-substituted cyclohexyl and cyclohexenyl carboxylic acids | GIVAUDAN CORPORATION (US) | 1986-08-19 | — | — | US | disclosed |
| US-4507290-A | CONTRACEPTIVE | WORLD HEALTH ORGANIZATION (CH) | 1985-03-26 | — | — | US | disclosed |
| EP-0110362-A2 | Fragrance and flavour compositions | L. GIVAUDAN & CIE Société Anonyme (CH) | 1984-06-13 | — | — | EP | disclosed |
| US-4357078-A | ELECTROOPTICS; DISPLAYING | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1982-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381177-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | ACMSD, GLS, ALDH7A1 | LMNA 2315/4885PLG 1751/4885PLAT 1849/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | LMNA 1656/4885PLG 1441/4885PLAT 1236/4885 |
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | LMNA 1656/4885PLG 1441/4885PLAT 1236/4885 |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | LMNA 3809/4885PLG 2277/4885PLAT 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.